Last month, Evotec entered into a multi-year collaboration deal with Pfizer PFE. Per the deal terms, this partnership with Pfizer will focus on early discovery research for metabolic and ...

Pfizer's RSI is trending upward, bouncing from the 50 support level, signaling potential stock strength and accumulation. Pfizer's KP.2-adapted COVID-19 vaccine received FDA approval, positioning ...

Pfizer and BioNTech may have a strong pedigree in the mRNA vaccine game, but, when it comes to flu, they’ve run up against the same problem as their peers—neutralizing influenza strain B.

Pfizer and BioNTech recently reported top-line results from a trial of its combination vaccine that was meant to protect against the flu and COVID-19. The partners' combination shot failed to ...

Pfizer is joining Eli Lilly in making certain of its prescription drugs available directly to consumers, a trend that worries some doctors and other health experts. The American College of ...

Pfizer recently reported a 3% increase in Q2'24 revenues to $13.3 billion, but the weak results came with a huge bonus to shareholders. The biopharma reported 14% operational growth when excluding ...

Aug 16 (Reuters) - Pfizer (PFE.N), opens new tab and BioNTech (22UAy.DE), opens new tab said a late-stage trial of their experimental mRNA vaccine to protect against influenza and COVID-19 found ...

NEW YORK & MAINZ, Germany--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE, “Pfizer”) and BioNTech SE (Nasdaq: BNTX, “BioNTech”) today announced top-line results from their Phase 3 clinical trial ...